Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

Carrying amount as of the balance sheet date of obligations due all related parties. For classified balance sheets, represents the current portion of such liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.

+ References+ Details

Related Party - Additional Information (Detail) (USD $)				3 Months Ended
Related Party - Additional Information (Detail) (USD $)	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012	Sep. 30, 2012 MD Anderson Cancer Center	Sep. 30, 2013 MD Anderson Cancer Center Clinical Trials	Sep. 30, 2012 MD Anderson Cancer Center Clinical Trials	Sep. 30, 2013 MD Anderson Cancer Center Research and Development Expense	Sep. 30, 2012 MD Anderson Cancer Center Research and Development Expense
Related Party Transaction [Line Items]
Accrued expense - related party	$ 52,050	$ 26,000		$ 50,000	$ 52,050	$ 39,000
Accrued license payments - related party	50,000	100,000
Cash paid to MD Anderson Cancer Center for expenses							15,000	47,582
Accounts payable - related party	0	8,582	8,582
Research and Development Expense					15,000	39,000
Patent Expense				$ 8,582